JP5911813B2 - Ｃｄ２０に対するモノクローナル抗体 - Google Patents

Ｃｄ２０に対するモノクローナル抗体 Download PDF

Info

Publication number
JP5911813B2
JP5911813B2 JP2012556068A JP2012556068A JP5911813B2 JP 5911813 B2 JP5911813 B2 JP 5911813B2 JP 2012556068 A JP2012556068 A JP 2012556068A JP 2012556068 A JP2012556068 A JP 2012556068A JP 5911813 B2 JP5911813 B2 JP 5911813B2
Authority
JP
Japan
Prior art keywords
antibody
canine
antibodies
cells
feline
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2012556068A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013520990A5 (https=
JP2013520990A (ja
Inventor
ジェネビーブ・ハンセン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aratana Therapeutics Inc
Original Assignee
Vet Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vet Therapeutics Inc filed Critical Vet Therapeutics Inc
Publication of JP2013520990A publication Critical patent/JP2013520990A/ja
Publication of JP2013520990A5 publication Critical patent/JP2013520990A5/ja
Application granted granted Critical
Publication of JP5911813B2 publication Critical patent/JP5911813B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Biophysics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biochemistry (AREA)
  • Pain & Pain Management (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2012556068A 2010-03-04 2011-03-04 Ｃｄ２０に対するモノクローナル抗体 Expired - Fee Related JP5911813B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US31044010P 2010-03-04 2010-03-04
US61/310,440 2010-03-04
PCT/US2011/000415 WO2011109108A1 (en) 2010-03-04 2011-03-04 Monoclonal antibodies directed to cd20

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016068492A Division JP2016179978A (ja) 2010-03-04 2016-03-30 Ｃｄ２０に対するモノクローナル抗体

Publications (3)

Publication Number Publication Date
JP2013520990A JP2013520990A (ja) 2013-06-10
JP2013520990A5 JP2013520990A5 (https=) 2014-04-17
JP5911813B2 true JP5911813B2 (ja) 2016-04-27

Family

ID=44542488

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2012556068A Expired - Fee Related JP5911813B2 (ja) 2010-03-04 2011-03-04 Ｃｄ２０に対するモノクローナル抗体
JP2016068492A Pending JP2016179978A (ja) 2010-03-04 2016-03-30 Ｃｄ２０に対するモノクローナル抗体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2016068492A Pending JP2016179978A (ja) 2010-03-04 2016-03-30 Ｃｄ２０に対するモノクローナル抗体

Country Status (6)

Country Link
EP (1) EP2542262A4 (https=)
JP (2) JP5911813B2 (https=)
AU (2) AU2011221553B2 (https=)
BR (1) BR112012022338A2 (https=)
CA (1) CA2791560A1 (https=)
WO (1) WO2011109108A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2411050A4 (en) 2009-03-25 2013-07-17 Vet Therapeutics Inc ANTIBODY REGIONS WITH A CONSTANT DOMAIN AND THEIR USE
EP2542258A4 (en) 2010-03-04 2013-08-21 Vet Therapeutics Inc ON CD52 MONOCLONAL ANTIBODIES
ES2704007T3 (es) * 2011-05-06 2019-03-13 Nexvet Australia Pty Ltd Anticuerpos anti-factor de crecimiento nervioso y procedimientos de preparación y uso de los mismos
AU2012328819B2 (en) * 2011-10-26 2017-08-03 Elanco Tiergesundheit Ag Monoclonal antibodies and methods of use
KR102131544B1 (ko) 2016-02-18 2020-07-07 엘랑코 유에스 인코포레이티드 키메라 개 항-cd20 항체
JP2019026625A (ja) * 2017-08-03 2019-02-21 日本全薬工業株式会社 抗イヌｃｄ２０モノクローナル抗体
JP2021059499A (ja) * 2019-10-03 2021-04-15 日本全薬工業株式会社 イヌｃｄ２０に対するモノクローナル抗体又は抗体フラグメント
EP4656205A1 (en) 2023-01-25 2025-12-03 Nippon Zenyaku Kogyo Co., Ltd. Method for treating canine b cell lymphoma

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JP3919830B2 (ja) * 1992-11-28 2007-05-30 財団法人化学及血清療法研究所 抗ネコヘルペスウイルス−１組換え抗体および該抗体をコードする遺伝子断片
JP3087696B2 (ja) 1997-07-25 2000-09-11 日本電気株式会社 分散メモリ型マルチプロセッサ・システム制御方法およびコンピュータ読み取り可能な記録媒体
EP1246607B1 (en) 1999-12-30 2007-06-27 Dana-Farber Cancer Institute, Inc. Proteoliposomes containing an integral membrane protein having one or more transmembrane domains
US7261890B2 (en) * 2001-12-21 2007-08-28 Idexx Laboratories, Inc. Methods for using canine immunoglobulin variable domains and caninized antibodies
WO2003068821A2 (en) * 2002-02-14 2003-08-21 Immunomedics, Inc. Anti-cd20 antibodies and fusion proteins thereof and methods of use
ZA200503075B (en) * 2002-11-07 2006-09-27 Immunogen Inc Anti-CD33 antibodies and method for treatment of acute myeloid leukemia using the same
US20080299546A1 (en) * 2004-02-10 2008-12-04 Nihon University Canine Cd20 Gene
US7531628B2 (en) * 2004-05-28 2009-05-12 Idexx Laboratories, Inc. Canine CD20 compositions
GB0707640D0 (en) 2007-04-20 2007-05-30 Strathclyde Acoustic deterrence
EP2331579B1 (en) 2008-09-04 2017-07-05 Vet Therapeutics, Inc. Monoclonal antibodies

Also Published As

Publication number Publication date
AU2016216710A1 (en) 2016-09-08
JP2016179978A (ja) 2016-10-13
AU2011221553B2 (en) 2016-05-26
EP2542262A1 (en) 2013-01-09
CA2791560A1 (en) 2011-09-09
AU2011221553A1 (en) 2012-10-25
EP2542262A4 (en) 2014-02-26
BR112012022338A2 (pt) 2017-02-14
JP2013520990A (ja) 2013-06-10
WO2011109108A1 (en) 2011-09-09

Similar Documents

Publication Publication Date Title
US9616120B2 (en) Monoclonal antibodies directed to CD20
US8337842B2 (en) Monoclonal antibodies
AU2011223547B2 (en) Monoclonal antibodies directed to CD52
TWI564306B (zh) 雙特異性抗體
JP5911813B2 (ja) Ｃｄ２０に対するモノクローナル抗体
AU2018220150A1 (en) Anti-CD47 Antibodies and Methods of Use Thereof
WO2020168555A1 (zh) Cd3抗原结合片段及其应用
JP2021531825A (ja) 葉酸受容体アルファに特異的な抗体
EP4292611A1 (en) Anti-cd112r antibody and use thereof
CN114981301B (zh) Pd1和vegfr2双结合剂
BR112020008438A2 (pt) anticorpos e métodos de uso
JP2026506565A (ja) 三重特異性抗原結合分子およびその使用
AU2014200771B2 (en) Monoclonal antibodies
CN117946270B (zh) 抗cd93抗体及其用途
AU2016216708A1 (en) Monoclonal antibodies
AU2009288700B2 (en) Monoclonal antibodies
CN119285769A (zh) 多特异性抗体及其医药用途
AU2016203429A1 (en) Binding Molecules to the Human OX40 Receptor

Legal Events

Date Code Title Description
RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20140120

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140227

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20140227

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150324

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150623

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150723

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150821

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150924

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20160301

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20160330

R150 Certificate of patent or registration of utility model

Ref document number: 5911813

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees